<p>FreeGulliver LLC 在第二季度购买了 MDxHealth SA (NASDAQ:MDXH - 免费报告) 的新股份，根据其最近向 SEC 提交的 13F 表格。该机构投资者购买了 123,546 股公司股票，价值约 273,000 美元。FreeGulliver LLC 在最近一个季度末拥有 MDxHealth 约 0.26% 的股份。</p>
<p>另外，AWM Investment Company Inc. 在第一季度将其在 MDxHealth 的股份提高了 10.6%。AWM Investment Company Inc. 目前拥有 5,221,282 股公司股票，价值 7,414,000 美元，此前在上个季度购买了额外的 499,992 股。</p>
<h2>MDxHealth 价格表现</h2>
<p>NASDAQ MDXH 周二开盘价为 3.57 美元。该公司的债务与股本比率为 13.81，流动比率为 1.31，速动比率为 1.22。该公司的市值为 1.6882 亿美元，市盈率为 -4.06，贝塔系数为 1.68。该公司有 50 日简单移动平均线为 4.28 美元，200 日简单移动平均线为 3.14 美元。MDxHealth SA 的 52 周低点为 1.35 美元，52 周高点为 5.33 美元。</p>
<p>MDxHealth (NASDAQ:MDXH - 获取免费报告) 最近一次发布财报是在 11 月 12 日星期三。该公司报告本季度每股收益（EPS）为 -0.16，低于分析师的共识预期（-0.12）0.04 美元。MDxHealth 的股本回报率为 -374.98%，净利润率为 -34.98%。该公司本季度的收入为 2743 万美元，而分析师的预期为 2411 万美元。MDxHealth 已设定其 2025 财年的每股收益指导。股票研究分析师预测 MDxHealth SA 本财年的每股收益将为 -1.15。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些券商最近对 MDXH 发布了报告。华尔街 Zen 在 8 月 30 日星期六的报告中将 MDxHealth 的评级上调至 “持有”。Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 MDxHealth 股票的 “卖出（e+）” 评级。TD Cowen 在 11 月 13 日星期四的研究报告中将 MDxHealth 股票的目标价从 5.00 美元上调至 7.00 美元，并给予该股票 “买入” 评级。BTIG Research 在 11 月 13 日星期四的报告中将 MDxHealth 股票的目标价从 6.00 美元上调至 7.00 美元，并给予该公司 “买入” 评级。最后，Lake Street Capital 在 11 月 13 日星期四的研究报告中将 MDxHealth 股票的目标价从 7.00 美元上调至 9.00 美元，并给予该股票 “买入” 评级。四位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，MDxHealth 目前的平均评级为 “适度买入”，共识目标价为 7.75 美元。</p>
<p><strong>阅读我们最新的 MDXH 股票分析</strong></p>
<h2>关于 MDxHealth</h2>
<p>(免费报告)</p>
<p>MDxHealth SA 是一家商业阶段的精准诊断公司，在美国、欧洲及国际市场提供泌尿科解决方案。其检测解决方案包括 Select mdx，一种用于前列腺癌的非侵入性尿液检测，测量两种与癌症相关的 mRNA 生物标志物的表达；Confirm mdx 用于前列腺癌组织检测，验证指导检测患者先前活检阴性组织中隐匿前列腺癌的表观遗传学检测；以及 Resolved mdx 用于尿路感染，识别针对患者感染的个性化有效抗生素选择。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 MDxHealth</li>
<li>股票情绪分析：如何运作</li>
<li>5 只零售股票可能会装点节日——或毁掉投资组合</li>
<li>REIT 股票 - 今天添加到您投资组合中的最佳 REIT 股票</li>
<li>D-Wave：是时候买入了吗？还是下跌才刚刚开始？</li>
<li>在经济衰退中与这些股息之王共度难关</li>
<li>Hims、Block 和 NRG 刚刚启动了大规模股票回购</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYSA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 MDxHealth 吗？</h2>
<p>在考虑 MDxHealth 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 MDxHealth 并不在名单上。</p>
<p>虽然 MDxHealth 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MDXH

<p>FreeGulliver LLC 根据其最新的 SEC 文件收购了 123,546 股 MDxHealth SA，估值约为 273,000 美元。这笔购买代表了 MDxHealth 约 0.26% 的股权。该公司的股票表现和财务指标也进行了讨论，包括最近的财报和分析师评级。MDxHealth 的评级为适度买入，市场共识目标价为 7.75 美元。该公司专注于泌尿科解决方案的精准诊断</p>

<p>FreeGulliver LLC purchased a new stake in MDxHealth SA (NASDAQ:MDXH - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 123,546 shares of the company's stock, valued at approximately $273,000. FreeGulliver LLC owned about 0.26% of MDxHealth at the end of the most recent quarter.</p>
<div class="lb-trans"><p>FreeGulliver LLC 在第二季度购买了 MDxHealth SA (NASDAQ:MDXH - 免费报告) 的新股份，根据其最近向 SEC 提交的 13F 表格。该机构投资者购买了 123,546 股公司股票，价值约 273,000 美元。FreeGulliver LLC 在最近一个季度末拥有 MDxHealth 约 0.26% 的股份。</p>
</div><p>Separately, AWM Investment Company Inc. lifted its stake in MDxHealth by 10.6% during the first quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company's stock valued at $7,414,000 after purchasing an additional 499,992 shares during the last quarter.</p>
<div class="lb-trans"><p>另外，AWM Investment Company Inc. 在第一季度将其在 MDxHealth 的股份提高了 10.6%。AWM Investment Company Inc. 目前拥有 5,221,282 股公司股票，价值 7,414,000 美元，此前在上个季度购买了额外的 499,992 股。</p>
</div><h2>MDxHealth Price Performance</h2>
<div class="lb-trans"><h2>MDxHealth 价格表现</h2>
</div><p>NASDAQ MDXH opened at $3.57 on Tuesday. The company has a debt-to-equity ratio of 13.81, a current ratio of 1.31 and a quick ratio of 1.22. The firm has a market capitalization of $168.82 million, a price-to-earnings ratio of -4.06 and a beta of 1.68. The company has a 50 day simple moving average of $4.28 and a 200-day simple moving average of $3.14. MDxHealth SA has a 52-week low of $1.35 and a 52-week high of $5.33.</p>
<div class="lb-trans"><p>NASDAQ MDXH 周二开盘价为 3.57 美元。该公司的债务与股本比率为 13.81，流动比率为 1.31，速动比率为 1.22。该公司的市值为 1.6882 亿美元，市盈率为 -4.06，贝塔系数为 1.68。该公司有 50 日简单移动平均线为 4.28 美元，200 日简单移动平均线为 3.14 美元。MDxHealth SA 的 52 周低点为 1.35 美元，52 周高点为 5.33 美元。</p>
</div><p>MDxHealth (NASDAQ:MDXH - Get Free Report) last released its earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.04). MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%.The company had revenue of $27.43 million during the quarter, compared to analysts' expectations of $24.11 million. MDxHealth has set its FY 2025 guidance at EPS. Equities research analysts predict that MDxHealth SA will post -1.15 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>MDxHealth (NASDAQ:MDXH - 获取免费报告) 最近一次发布财报是在 11 月 12 日星期三。该公司报告本季度每股收益（EPS）为 -0.16，低于分析师的共识预期（-0.12）0.04 美元。MDxHealth 的股本回报率为 -374.98%，净利润率为 -34.98%。该公司本季度的收入为 2743 万美元，而分析师的预期为 2411 万美元。MDxHealth 已设定其 2025 财年的每股收益指导。股票研究分析师预测 MDxHealth SA 本财年的每股收益将为 -1.15。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of brokerages recently issued reports on MDXH. Wall Street Zen upgraded MDxHealth to a &#34;hold&#34; rating in a report on Saturday, August 30th. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of MDxHealth in a report on Wednesday, October 8th. TD Cowen lifted their target price on shares of MDxHealth from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, November 13th. BTIG Research boosted their price target on shares of MDxHealth from $6.00 to $7.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, November 13th. Finally, Lake Street Capital raised their price objective on shares of MDxHealth from $7.00 to $9.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, MDxHealth presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $7.75.</p>
<div class="lb-trans"><p>一些券商最近对 MDXH 发布了报告。华尔街 Zen 在 8 月 30 日星期六的报告中将 MDxHealth 的评级上调至 “持有”。Weiss Ratings 在 10 月 8 日星期三的报告中重申了对 MDxHealth 股票的 “卖出（e+）” 评级。TD Cowen 在 11 月 13 日星期四的研究报告中将 MDxHealth 股票的目标价从 5.00 美元上调至 7.00 美元，并给予该股票 “买入” 评级。BTIG Research 在 11 月 13 日星期四的报告中将 MDxHealth 股票的目标价从 6.00 美元上调至 7.00 美元，并给予该公司 “买入” 评级。最后，Lake Street Capital 在 11 月 13 日星期四的研究报告中将 MDxHealth 股票的目标价从 7.00 美元上调至 9.00 美元，并给予该股票 “买入” 评级。四位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，MDxHealth 目前的平均评级为 “适度买入”，共识目标价为 7.75 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on MDXH</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 MDXH 股票分析</strong></p>
</div><h2>About MDxHealth</h2>
<div class="lb-trans"><h2>关于 MDxHealth</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.</p>
<div class="lb-trans"><p>MDxHealth SA 是一家商业阶段的精准诊断公司，在美国、欧洲及国际市场提供泌尿科解决方案。其检测解决方案包括 Select mdx，一种用于前列腺癌的非侵入性尿液检测，测量两种与癌症相关的 mRNA 生物标志物的表达；Confirm mdx 用于前列腺癌组织检测，验证指导检测患者先前活检阴性组织中隐匿前列腺癌的表观遗传学检测；以及 Resolved mdx 用于尿路感染，识别针对患者感染的个性化有效抗生素选择。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than MDxHealth</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>5 Retail Stocks That Could Deck the Halls—or Wreck Portfolios</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?</li>
<li>Ride Out The Recession With These Dividend Kings</li>
<li>Hims, Block, and NRG Just Launched Huge Stock Buybacks</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 MDxHealth</li>
<li>股票情绪分析：如何运作</li>
<li>5 只零售股票可能会装点节日——或毁掉投资组合</li>
<li>REIT 股票 - 今天添加到您投资组合中的最佳 REIT 股票</li>
<li>D-Wave：是时候买入了吗？还是下跌才刚刚开始？</li>
<li>在经济衰退中与这些股息之王共度难关</li>
<li>Hims、Block 和 NRG 刚刚启动了大规模股票回购</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYSA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MDXH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MDxHealth Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 MDxHealth 吗？</h2>
</div><p>Before you consider MDxHealth, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MDxHealth 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MDxHealth wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 MDxHealth 并不在名单上。</p>
</div><p>While MDxHealth currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MDxHealth 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

FreeGulliver LLC 购入了 123,546 股 MDxHealth SA $MDXH 的股票